4basebio (LON:4BB - Get Free Report) announced its earnings results on Tuesday. The company reported GBX (0.94) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.
4basebio Trading Up 1.7%
LON 4BB traded up GBX 19 ($0.26) on Friday, hitting GBX 1,129 ($15.19). The company's stock had a trading volume of 108 shares, compared to its average volume of 926. 4basebio has a 52-week low of GBX 1,070 ($14.40) and a 52-week high of GBX 1,820 ($24.49). The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The company's 50-day simple moving average is GBX 1,132.60 and its 200 day simple moving average is GBX 1,172.62. The firm has a market cap of £144.62 million, a P/E ratio of -1,447.44 and a beta of 1.09.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada reaffirmed an "outperform" rating and set a GBX 1,600 ($21.53) price objective on shares of 4basebio in a report on Thursday, March 13th.
View Our Latest Report on 4basebio
Insiders Place Their Bets
In other news, insider Heikki Lanckriet bought 2,400 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was bought at an average price of GBX 1,205 ($16.21) per share, for a total transaction of £28,920 ($38,912.81). Company insiders own 68.44% of the company's stock.
About 4basebio
(
Get Free Report)
4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.
Recommended Stories
Before you consider 4basebio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4basebio wasn't on the list.
While 4basebio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
